메뉴 건너뛰기




Volumn 412, Issue 1-2, 2011, Pages 79-85

Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays

Author keywords

Genotyping; Helicase Dependent Amplification (HDA); Isothermal amplification; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA; WARFARIN;

EID: 78650516123     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.09.014     Document Type: Article
Times cited : (14)

References (39)
  • 2
    • 45949103309 scopus 로고    scopus 로고
    • Pharmacology and management of the vitamin K antagonists: American College of chest physicians evidence-based clinical practice guidelines (8th Edition)
    • Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonists: American College of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133:160S-198S.
    • (2008) Chest , vol.133
    • Ansell, J.1    Hirsh, J.2    Hylek, E.3    Jacobson, A.4    Crowther, M.5    Palareti, G.6
  • 3
    • 33845500310 scopus 로고    scopus 로고
    • Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency
    • Baglin T.P., Cousins D., Keeling D.M., Perry D.J., Watson H.G. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol 2007, 136:26-29.
    • (2007) Br J Haematol , vol.136 , pp. 26-29
    • Baglin, T.P.1    Cousins, D.2    Keeling, D.M.3    Perry, D.J.4    Watson, H.G.5
  • 4
    • 39449137238 scopus 로고    scopus 로고
    • Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
    • Flockhart D.A., O'Kane D., Williams M.S., et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008, 10:139-150.
    • (2008) Genet Med , vol.10 , pp. 139-150
    • Flockhart, D.A.1    O'Kane, D.2    Williams, M.S.3
  • 5
    • 33645466135 scopus 로고    scopus 로고
    • Long-term anticoagulant therapy in patients with coronary artery disease
    • Husted S.E., Ziegler B.K., Kher A. Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J 2006, 27:913-919.
    • (2006) Eur Heart J , vol.27 , pp. 913-919
    • Husted, S.E.1    Ziegler, B.K.2    Kher, A.3
  • 6
    • 45949095568 scopus 로고    scopus 로고
    • Antithrombotic therapy in atrial fibrillation: American College of chest physicians evidence-based clinical practice guidelines (8th edition)
    • Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:546S-592S.
    • (2008) Chest , vol.133
    • Singer, D.E.1    Albers, G.W.2    Dalen, J.E.3
  • 7
  • 9
    • 24944503322 scopus 로고    scopus 로고
    • A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
    • Yuan H.Y., Chen J.J., Lee M.T., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005, 14:1745-1751.
    • (2005) Hum Mol Genet , vol.14 , pp. 1745-1751
    • Yuan, H.Y.1    Chen, J.J.2    Lee, M.T.3
  • 10
    • 0033608466 scopus 로고    scopus 로고
    • Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    • Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353:717-719.
    • (1999) Lancet , vol.353 , pp. 717-719
    • Aithal, G.P.1    Day, C.P.2    Kesteven, P.J.3    Daly, A.K.4
  • 11
    • 31944446445 scopus 로고    scopus 로고
    • Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry
    • Reynolds M.R., Shah J., Essebag V., et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006, 97:538-543.
    • (2006) Am J Cardiol , vol.97 , pp. 538-543
    • Reynolds, M.R.1    Shah, J.2    Essebag, V.3
  • 12
    • 10444278105 scopus 로고    scopus 로고
    • Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis
    • Reynolds M.W., Fahrbach K., Hauch O., et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004, 126:1938-1945.
    • (2004) Chest , vol.126 , pp. 1938-1945
    • Reynolds, M.W.1    Fahrbach, K.2    Hauch, O.3
  • 13
    • 51649084617 scopus 로고    scopus 로고
    • Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
    • Wang D., Chen H., Momary K.M., Cavallari L.H., Johnson J.A., Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008, 112:1013-1021.
    • (2008) Blood , vol.112 , pp. 1013-1021
    • Wang, D.1    Chen, H.2    Momary, K.M.3    Cavallari, L.H.4    Johnson, J.A.5    Sadee, W.6
  • 14
    • 0034872136 scopus 로고    scopus 로고
    • Pharmacogenetics of warfarin elimination and its clinical implications
    • Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001, 40:587-603.
    • (2001) Clin Pharmacokinet , vol.40 , pp. 587-603
    • Takahashi, H.1    Echizen, H.2
  • 16
    • 0142103762 scopus 로고    scopus 로고
    • Genetic regulation of warfarin metabolism and response
    • Daly A.K., Aithal G.P. Genetic regulation of warfarin metabolism and response. Semin Vasc Med 2003, 3:231-238.
    • (2003) Semin Vasc Med , vol.3 , pp. 231-238
    • Daly, A.K.1    Aithal, G.P.2
  • 17
    • 0037565623 scopus 로고    scopus 로고
    • Pharmacogenetics of oral anticoagulants
    • Daly A.K., King B.P. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003, 13:247-252.
    • (2003) Pharmacogenetics , vol.13 , pp. 247-252
    • Daly, A.K.1    King, B.P.2
  • 18
    • 13844315559 scopus 로고    scopus 로고
    • CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis
    • Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005, 7:97-104.
    • (2005) Genet Med , vol.7 , pp. 97-104
    • Sanderson, S.1    Emery, J.2    Higgins, J.3
  • 19
    • 17944366735 scopus 로고    scopus 로고
    • Interindividual variability in sensitivity to warfarin-nature or nurture?
    • Loebstein R., Yonath H., Peleg D., et al. Interindividual variability in sensitivity to warfarin-nature or nurture?. Clin Pharmacol Ther 2001, 70:159-164.
    • (2001) Clin Pharmacol Ther , vol.70 , pp. 159-164
    • Loebstein, R.1    Yonath, H.2    Peleg, D.3
  • 20
    • 0037012465 scopus 로고    scopus 로고
    • Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
    • Higashi M.K., Veenstra D.L., Kondo L.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
    • (2002) JAMA , vol.287 , pp. 1690-1698
    • Higashi, M.K.1    Veenstra, D.L.2    Kondo, L.M.3
  • 21
    • 0036914221 scopus 로고    scopus 로고
    • Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
    • Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002, 72:702-710.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 702-710
    • Scordo, M.G.1    Pengo, V.2    Spina, E.3    Dahl, M.L.4    Gusella, M.5    Padrini, R.6
  • 22
    • 0042915883 scopus 로고    scopus 로고
    • Warfarin dose adjustments based on CYP2C9 genetic polymorphisms
    • Linder M.W., Looney S., Adams J.E., et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis 2002, 14:227-232.
    • (2002) J Thromb Thrombolysis , vol.14 , pp. 227-232
    • Linder, M.W.1    Looney, S.2    Adams, J.E.3
  • 23
    • 1542346414 scopus 로고    scopus 로고
    • Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
    • Kamali F., Khan T.I., King B.P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004, 75:204-212.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 204-212
    • Kamali, F.1    Khan, T.I.2    King, B.P.3
  • 24
    • 1342332251 scopus 로고    scopus 로고
    • Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
    • Wadelius M., Sorlin K., Wallerman O., et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004, 4:40-48.
    • (2004) Pharmacogenomics J , vol.4 , pp. 40-48
    • Wadelius, M.1    Sorlin, K.2    Wallerman, O.3
  • 25
    • 1542346407 scopus 로고    scopus 로고
    • CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy
    • Peyvandi F., Spreafico M., Siboni S.M., Moia M., Mannucci P.M. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004, 75:198-203.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 198-203
    • Peyvandi, F.1    Spreafico, M.2    Siboni, S.M.3    Moia, M.4    Mannucci, P.M.5
  • 26
    • 72949112021 scopus 로고    scopus 로고
    • Warfarin sensitivity genotyping: a review of the literature and summary of patient experience
    • Moyer T.P., O'Kane D.J., Baudhuin L.M., et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc 2009, 84:1079-1094.
    • (2009) Mayo Clin Proc , vol.84 , pp. 1079-1094
    • Moyer, T.P.1    O'Kane, D.J.2    Baudhuin, L.M.3
  • 27
    • 0029894980 scopus 로고    scopus 로고
    • Extremely sensitive, background-free gene detection using binary probes and beta replicase
    • Tyagi S., Landegren U., Tazi M., Lizardi P.M., Kramer F.R. Extremely sensitive, background-free gene detection using binary probes and beta replicase. Proc Natl Acad Sci USA 1996, 93:5395-5400.
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 5395-5400
    • Tyagi, S.1    Landegren, U.2    Tazi, M.3    Lizardi, P.M.4    Kramer, F.R.5
  • 30
    • 0026547223 scopus 로고
    • Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system
    • Walker G.T., Little M.C., Nadeau J.G., Shank D.D. Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system. Proc Natl Acad Sci USA 1992, 89:392-396.
    • (1992) Proc Natl Acad Sci USA , vol.89 , pp. 392-396
    • Walker, G.T.1    Little, M.C.2    Nadeau, J.G.3    Shank, D.D.4
  • 32
    • 0031831323 scopus 로고    scopus 로고
    • Mutation detection and single-molecule counting using isothermal rolling-circle amplification
    • Lizardi P.M., Huang X., Zhu Z., Bray-Ward P., Thomas D.C., Ward D.C. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet 1998, 19:225-232.
    • (1998) Nat Genet , vol.19 , pp. 225-232
    • Lizardi, P.M.1    Huang, X.2    Zhu, Z.3    Bray-Ward, P.4    Thomas, D.C.5    Ward, D.C.6
  • 33
    • 0032510768 scopus 로고    scopus 로고
    • Amplification of target-specific, ligation-dependent circular probe
    • Zhang D.Y., Brandwein M., Hsuih T.C., Li H. Amplification of target-specific, ligation-dependent circular probe. Gene 1998, 211:277-285.
    • (1998) Gene , vol.211 , pp. 277-285
    • Zhang, D.Y.1    Brandwein, M.2    Hsuih, T.C.3    Li, H.4
  • 34
    • 23844480384 scopus 로고    scopus 로고
    • Characterization of a thermostable UvrD helicase and its participation in helicase-dependent amplification
    • An L., Tang W., Ranalli T.A., Kim H.J., Wytiaz J., Kong H. Characterization of a thermostable UvrD helicase and its participation in helicase-dependent amplification. J Biol Chem 2005, 280:28952-28958.
    • (2005) J Biol Chem , vol.280 , pp. 28952-28958
    • An, L.1    Tang, W.2    Ranalli, T.A.3    Kim, H.J.4    Wytiaz, J.5    Kong, H.6
  • 35
    • 4444258850 scopus 로고    scopus 로고
    • Helicase-dependent isothermal DNA amplification
    • Vincent M., Xu Y., Kong H. Helicase-dependent isothermal DNA amplification. EMBO Rep 2004, 5:795-800.
    • (2004) EMBO Rep , vol.5 , pp. 795-800
    • Vincent, M.1    Xu, Y.2    Kong, H.3
  • 36
    • 57349156882 scopus 로고    scopus 로고
    • Development of isothermal TaqMan assays for detection of biothreat organisms
    • Tong Y., Tang W., Kim H.J., Pan X., Ranalli T., Kong H. Development of isothermal TaqMan assays for detection of biothreat organisms. Biotechniques 2008, 45:543-557.
    • (2008) Biotechniques , vol.45 , pp. 543-557
    • Tong, Y.1    Tang, W.2    Kim, H.J.3    Pan, X.4    Ranalli, T.5    Kong, H.6
  • 37
    • 42549147383 scopus 로고    scopus 로고
    • Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose
    • King C.R., Porche-Sorbet R.M., Gage B.F., et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008, 129:876-883.
    • (2008) Am J Clin Pathol , vol.129 , pp. 876-883
    • King, C.R.1    Porche-Sorbet, R.M.2    Gage, B.F.3
  • 38
    • 33845260086 scopus 로고    scopus 로고
    • Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study
    • Carlquist J.F., Horne B.D., Muhlestein J.B., et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006, 22:191-197.
    • (2006) J Thromb Thrombolysis , vol.22 , pp. 191-197
    • Carlquist, J.F.1    Horne, B.D.2    Muhlestein, J.B.3
  • 39
    • 34347403221 scopus 로고    scopus 로고
    • Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes
    • Zhu Y., Shennan M., Reynolds K.K., et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007, 53:1199-1205.
    • (2007) Clin Chem , vol.53 , pp. 1199-1205
    • Zhu, Y.1    Shennan, M.2    Reynolds, K.K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.